Impedance Responses Reveal β2-Adrenergic Receptor Signaling Pluridimensionality and Allow Classification of Ligands with Distinct Signaling Profiles

Abstract

The discovery that drugs targeting a single G protein-coupled receptor (GPCR) can differentially modulate distinct subsets of the receptor signaling repertoire has created a challenge for drug discovery at these important therapeutic targets. Here, we demonstrate that a single label-free assay based on cellular impedance provides a real-time integration of multiple signaling events engaged upon GPCR activation. Stimulation of the β2-adrenergic receptor (β2AR) in living cells with the prototypical agonist isoproterenol generated a complex, multi-featured impedance response over time. Selective pharmacological inhibition of specific arms of the β2AR signaling network revealed the differential contribution of Gs-, Gi- and Gβγ-dependent signaling events, including activation of the canonical cAMP and ERK1/2 pathways, to specific components of the impedance response. Further dissection revealed the essential role of intracellular Ca2+ in the impedance response and led to the discovery of a novel β2AR-promoted Ca2+ mobilization event. Recognizing that impedance responses provide an integrative assessment of ligand activity, we screened a collection of β-adrenergic ligands to determine if differences in the signaling repertoire engaged by compounds would lead to distinct impedance signatures. An unsupervised clustering analysis of the impedance responses revealed the existence of 5 distinct compound classes, revealing a richer signaling texture than previously recognized for this receptor. Taken together, these data indicate that the pluridimensionality of GPCR signaling can be captured using integrative approaches to provide a comprehensive readout of drug activity.

Plasma membrane translocation of REDD1 governed by GPCRs contributes to mTORC1 activation

“…In addition, coupling to multiple G-proteins might be more pronounced if the receptors are overexpressed and could depend upon the degree of biased agonism of the tested ligand (Galandrin et al, 2007). Instead, in our study, receptors were endogenously expressed and all the agonists were either the natural endogenous agonists (ACh, ET-1, CXCL12, LPA) or behave like natural agonists in terms of ligand signaling profile (Iso) (Stallaert et al, 2012) with one exception, NECA, that might induce Gq-coupling to Ade2BR (Gao et al, 1999).…”

Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist

“…Both phenomena exploit the dynamic nature of GPCRs, where chemically distinct ligands stabilize different subsets of receptor conformations to yield new interactive properties of the receptor to other ligands (allosteric modulation) or intracellular effectors (biased agonism) (41). To date, biased ligands for GPCRs have been identified through two general approaches: compound screening at preselected pathways (often β-arrestin-vs. G protein-dependent) or retrospectively by taking established compounds with divergent pharmacologies and profiling them broadly to identify potential differentiating signatures (42)(43)(44)(45)(46). The first approach relies on mechanistic rationales to guide the choice of pathway(s) chosen for screening.…”

Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells

“…In the case of GPCRs and cytokine receptors, pluripotency of signaling is a growing area of pharmacology where one aims at finding agonists that bias signaling via a receptor to a particular down streaming pathway (19)(20)(21)(22)(23). To accomplish this, one needs to test a large number of agonists.…”